Virid­i­an’s $150M of­fer­ing; Sur­rozen scraps IBD drug can­di­date; As­sem­bly ends deal with In­di­ana Uni­ver­si­ty

Plus, news about Vor Bio, Vaxxin­i­ty, Im­mat­ics and Cer­tis On­col­o­gy:

Virid­i­an Ther­a­peu­tics’ $150M pub­lic of­fer­ing: The Waltham, MA-based biotech is sell­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.